EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Multizentrische Studie

Debio 0123, a WEE1 kinase inhibitor: Phase 1 results from dose escalation in patients with advanced solid tumors

Kyriakos P Papadopoulos, Manish R Sharma, Reinhard Dummer, Ilaria Colombo, Egle Ramelyte, Leigh Seamon, Drew W Rasco, Victor Rodriguez-Freixinos, Vito Dozio, Tri Tat, Noemie Luong, Caroline Mathon und 8 weitere

European Journal of Cancer · 2026

DOI: 10.1016/j.ejca.2026.116792 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift European Journal of Cancer, 2026. Verfasst von Kyriakos P Papadopoulos und 19 weiteren Autor:innen. Beteiligte Einrichtung: START Center for Cancer Research, San Antonio, TX, USA. Electronic address: Kyri.Papadopoulos@startresearch.com. Hauptthemen laut MEDLINE: Cell Cycle Proteins, Neoplasms, Protein Kinase Inhibitors, Nuclear Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cell Cycle ProteinsNeoplasmsProtein Kinase InhibitorsNuclear ProteinsAntineoplastic AgentsHumansMaleFemaleMiddle AgedAgedAdultProtein-Tyrosine KinasesDose-Response Relationship, DrugMaximum Tolerated DoseTreatment OutcomeAged, 80 and overPyrazolesPyrimidinones

Stichwörter der Autor:innen

CDC2CDK1Debio 0123Relapsed/refractory advanced solid tumorsWEE1 inhibitor

Substanzen

WEE1 protein, humanCell Cycle ProteinsProtein-Tyrosine KinasesProtein Kinase InhibitorsNuclear ProteinsAntineoplastic AgentsadavosertibPyrazolesPyrimidinones

Autor:innen und Institutionen

  • START Center for Cancer Research, San Antonio, TX, USA. Electronic address: Kyri.Papadopoulos@startresearch.com.
  • START Center for Cancer Research - Midwest, Grand Rapids, MI, USA.
  • Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.
  • Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland.
  • START Center for Cancer Research, San Antonio, TX, USA.
  • Debiopharm International SA, Lausanne, Switzerland.

Zitieren

APA

Papadopoulos, K. P., Sharma, M. R., Dummer, R., Colombo, I., Ramelyte, E., Seamon, L., Rasco, D. W., Rodriguez-Freixinos, V., Dozio, V., Tat, T., Luong, N., Mathon, C., Fuchs, J., Massiere, F., Hurynovich, A., Omar, M., Micallef, S., Bellon, A., Rodrigo Imedio, E., & Stathis, A. (2026). Debio 0123, a WEE1 kinase inhibitor: Phase 1 results from dose escalation in patients with advanced solid tumors. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2026.116792

Vancouver

Papadopoulos KP, Sharma MR, Dummer R, Colombo I, Ramelyte E, Seamon L, et al. Debio 0123, a WEE1 kinase inhibitor: Phase 1 results from dose escalation in patients with advanced solid tumors. European Journal of Cancer. 2026. doi:10.1016/j.ejca.2026.116792

BibTeX
@article{Papadopoulos2026,
  author = {Papadopoulos, Kyriakos P and Sharma, Manish R and Dummer, Reinhard and Colombo, Ilaria and Ramelyte, Egle and Seamon, Leigh and Rasco, Drew W and Rodriguez-Freixinos, Victor and Dozio, Vito and Tat, Tri and Luong, Noemie and Mathon, Caroline and Fuchs, Jeannette and Massiere, Frederic and Hurynovich, Aliaksandr and Omar, Mokhtar and Micallef, Sandrine and Bellon, Anne and Rodrigo Imedio, Esteban and Stathis, Anastasios},
  title = {Debio 0123, a WEE1 kinase inhibitor: Phase 1 results from dose escalation in patients with advanced solid tumors},
  journal = {European Journal of Cancer},
  year = {2026},
  doi = {10.1016/j.ejca.2026.116792}
}
Kostenlos starten →